Sickle Cell Disease Association of America Inc. statement about gene therapy approval chicagocrusader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chicagocrusader.com Daily Mail and Mail on Sunday newspapers.
bluebird bio (BLUE) Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Severe vaso-occlusive events were eliminated for 94% of evaluable patients and all VOEs were eliminated for 88% of evaluable patients between 6 and 18 months post-infusion
LYFGENIA is the most.